Business Description
Clearmind Medicine Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, focused on developing new treatments for conditions that have few effective options today, including alcohol dependency, eating disorders, obesity, anxiety, PTSD, and depression. Its lead compound, MEAI, is being studied both as a medical treatment and as a consumer alternative to alcohol, while its drug candidate CM-CMND-001 is currently in Phase I/IIa clinical trials. The company works with several research and development partners, including the Hebrew University of Jerusalem and SciSparc Ltd., to advance its pipeline across a range of metabolic and mental health conditions.
